basic sceince research

BASIC SCIENCE RESEARCH PROGRAM

Research Accomplishments

Research projects are integrated under the following themes which are highly interactive and are beyond the conventional boundaries of a given expertise area and truly represent the CPDR paradigm:

  • Translational CaP Genomics and Proteomics
  • Novel CaP Cell Culture Models
  • CaP Molecular Genetics
  • Hormonal Mechanisms of CaP


Translational CaP Genomics and Proteomics

Translational research of cancer cell and molecular biology-derived discoveries in the pre-clinical or clinical research setting has been the priority of CPDR since its inception. A highly multi-disciplinary research environment of urologists, cancer cell and molecular biologists, genitourinary pathologists, bioinformatics and medical informatics experts, bio-statisticians, medical technologists and regulatory affairs experts supports the CPDR enterprise. Well-characterized CPDR biospecimens banks, recent discoveries showing consistent gene expression alterations in CaP and development of promising new molecular diagnostic technologies, have provided an optimal setting for CPDR to focus in the translational research areas, where we already have developed expertise or in the areas where new initiatives are needed.

Novel Cell Culture Models of CaP

The Prostate Cell Center was established in the newly-renovated CPDR laboratory at the Department of Surgery, USUHS, in January 2000 and has been very active over the years. The Prostate Cell Center has made major advances in the generation of short-term cultures from primary tumors of prostate cancer patients. (1) Total cell strains generated from primary tumors are 134, (2) the number of cell strains generated from normal tissue from the same patient are 72, (3) five well-characterized telomerase-immortalized human CaP cell lines from the tumor of African American and caucasian CaP patients. These cells are critical to the development and use of in vitro models and for the identification of novel therapeutic targets of prostate cancer.

CaP Molecular Genetics

Since its inception, CPDR-BRP has embraced the goal of defining CaP-specific genetic alterations that characterize the disease onset and/or progression. Genetic alterations that are "critical" in the genesis of CaP or molecular alterations that "consistently associate" with CaP will provide definitive molecular targets for the development of bio-markers and new therapeutic targets. This goal has become increasingly more apparent as most of the frequent gene alterations associated with other common human cancers such as breast cancer, colon cancer or lung cancer, do not seem to play a significant role in CaP.

Defining Androgen Signaling in CaP Onset and Progression

Androgen signaling is extremely important in the life and death of the prostate gland and is believed to play an important role in prostate cancer. Hormonal therapy, the most common treatment strategy for the treatment of metastatic prostate cancer works by inhibiting androgen signaling. Accumulating evidence suggests that alterations of androgen signaling in prostate cancer may involve structural or functional alterations of the critical genes at numerous points in the pathway.

BSRP Home | BSRP Leadership | Gene Expression Data | BSRP Staff

CURRENT EVENTS


August 21, 2014

ERG Monoclonal Antibody [9FY] Patent Issued To The Uniformed Services University Of The Health Sciences Center For Prostate Disease Research & Biocare Medical

Concord, CA – The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has been awarded a patent in the United States (Patent No: US 8,765,916 B2) and Europe for ERG monoclonal antibodies. The patent is pending in Australia, Canada and Japan. ERG mouse antibody 9FY is a rigorously characterized antibody for its specificity of the ERG protein detection among the closely related members of the ETS transcription factor family in biological specimens.

Read Full Article

 

August 6, 2014

Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX® Prostate Cancer Test with Multiple Clinical Endpoints

Redwood City, CA – PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a ...

Read Full Article

 

WRNMMC UsToo! Newsletter

Read the AUGUST 2014 Newsletter